U.S. market Closed. Opens in 2 hours 54 minutes

XERS | Xeris Biopharma Holdings, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 2.9650 - 3.08
52 Week Range 1.6900 - 3.64
Beta 1.31
Implied Volatility 153.92%
IV Rank 42.18%
Day's Volume 1,049,869
Average Volume 1,620,253
Shares Outstanding 149,081,000
Market Cap 456,187,860
Sector Healthcare
Industry Biotechnology
IPO Date 2018-06-21
Valuation
Profitability
Growth
Health
P/E Ratio -7.12
Forward P/E Ratio N/A
EPS -0.43
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 377
Country USA
Website XERS
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
XERS's peers: PLX, MCRB, CDTX, IBRX, GRTX, MREO, TERN, PDSB, INZY, HOOK, XFOR, DAWN, EFTR, ELEV, HEPA
*Chart delayed
Analyzing fundamentals for XERS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see XERS Fundamentals page.

Watching at XERS technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on XERS Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙